(+)-Morphinan TLR9 Antagonists Block Glial Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic and acute pain, inflammatory disorders, autoimmune disorders, neurodegenerative disorders, and cancer often fail to effectively target activated glial cells, which contribute to these conditions by releasing pro-inflammatory factors, leading to inadequate pain control and inflammation management.
Innovation Solution
Development of (+)-morphinan compounds that inhibit Toll-like receptor 9 (TLR9) activation, thereby blocking glial cell activation, which can be used to treat conditions such as traumatic pain, neuropathic pain, inflammatory disorders, acetaminophen toxicity, autoimmune disorders, neurodegenerative disorders, and cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pain and inflammation treatments are used, then symptom relief is achieved, but activated glial cells remain untreated and continue to release pro-inflammatory factors
Solution Approach 1:
The patent extracts and targets the specific mechanism of glial cell activation through TLR9, separating this harmful pathway from conventional non-specific pain treatment approaches. By identifying and blocking the TLR9 receptor on glial cells, the invention removes the source of pro-inflammatory factor release while maintaining pain relief through alternative mechanisms.
Solution Approach 2:
The patent introduces TLR9 antagonists as intermediary substances that mediate between the pain stimulus and the glial cell response. These antagonists bind to TLR9 receptors on glial cells, preventing pathogen-associated molecular patterns from activating the cells, thus blocking the harmful pro-inflammatory cascade without directly addressing pain perception.
2Object-generated harmful factors
If TLR9 antagonists are developed to block glial cell activation, then pro-inflammatory factor release is reduced, but new compound classes must be identified and validated
Solution Approach 1:
The patent identifies TLR9 as a universal target that mediates multiple disease states including pain, inflammation, autoimmune disorders, and neurodegenerative conditions. By developing antagonists that block this single receptor, the invention achieves multi-functional therapeutic effects across different disease categories, simplifying the drug development process compared to treating each condition separately.
Solution Approach 2:
The patent performs preliminary identification and characterization of TLR9 antagonists through in vitro assays before clinical application. By pre-screening compound libraries for TLR9 blocking activity and validating mechanism of action in controlled settings, the invention reduces the complexity and risk of subsequent clinical trial processes.
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
The present invention provides (+)-morphinans comprising Toll-like receptor 9 (TLR9) antagonist activity, as well as a method for identifying (+)-morphinans that may be therapeutically effective by determining whether the (+)-morphinan inhibits the activation of TLR9. Also provided are methods of using the (+)-morphinans comprising TLR9 antagonist activity to treat conditions such as traumatic pain, neuropathic pain, inflammatory disorders, acetaminophen toxicity, autoimmune disorders, neurodegenerative disorders, and cancer.